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Abstract
Background: HLTF (Helicase-like Transcription Factor) is a DNA helicase protein homologous to the SWI/SNF family
involved in the maintenance of genomic stability and the regulation of gene expression. HLTF has also been found
to be frequently inactivated by promoter hypermethylation in human colon cancers. Whether this epigenetic event
is required for intestinal carcinogenesis is unknown.
Results: To address the role of loss of HLTF function in the development of intestinal cancer, we generated Hltf
deficient mice. These mutant mice showed normal development, and did not develop intestinal tumors, indicating
that loss of Hltf function by itself is insufficient to induce the formation of intestinal cancer. On the Apc
min/+
mutant background, Hltf
- deficiency was found to significantly increase the formation of intestinal adenocarcinoma
and colon cancers. Cytogenetic analysis of colon tumor cells from Hltf
-/-/Apc
min/+ mice revealed a high incidence
of gross chromosomal instabilities, including Robertsonian fusions, chromosomal fragments and aneuploidy. None
of these genetic alterations were observed in the colon tumor cells derived from Apc
min/+ mice. Increased tumor
growth and genomic instability was also demonstrated in HCT116 human colon cancer cells in which HLTF
expression was significantly decreased.
Conclusion: Taken together, our results demonstrate that loss of HLTF function promotes the malignant
transformation of intestinal or colonic adenomas to carcinomas by inducing genomic instability. Our findings
highly suggest that epigenetic inactivation of HLTF, as found in most human colon cancers, could play an
important role in the progression of colon tumors to malignant cancer.
Keywords: HLTF, Mouse gene-targeting, Adenomatous polyposis coli (Apc), Intestinal adenocarcinoma, Colonic
tumor or cancer, Chromosomal instability, HCT116 cells
Background
Human colon cancer is the second leading cause of can-
cer-related death in developed countries. About 50% of
the Western population develops adenomatous polyps (a
benign colon tumor) by the age of 70, and the lifetime
risk for colon cancer is estimated to be 5% [1]. The for-
mation of colon cancer involves a multiple-step process,
starting from a small adenomatous polyp and followed
by the development of a large adenoma with dysplasia
that ultimately leads to the formation of invasive carci-
noma (see the recent review by Fearon ER [2]). It is
widely accepted that most human colon cancers are
initiated by the inactivation of the Adenomatous
Polyposis Coli (APC)/Wnt signaling pathway and then
progress as the result of a series of mutational activation
of oncogenes coupled with the inactivation of tumor-
suppressor genes [2,3]. Apart from genetic mutations,
epigenetic alterations, particularly aberrant CpG island
methylation, have been demonstrated as a major alterna-
tive mechanism for suppressing gene function during
the development of colon cancer [4-6]. To date, many
genes that are epigenetically silenced in human colon
cancers as well as in colonic adenomas have been identi-
fied. However, the function of many of these genes in
colon carcinogenesis is still largely unknown. In this
study, we have characterized the role of one of these
methylated genes, termed Helicase-like Transcription
Factor (HLTF), in intestinal carcinogenesis.
HLTF (SMARCA3 in OMIM) is homologous to the
SWI/SNF family of chromatin remodelers [7-10].
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binding protein that could interact with several gene
promoters and enhancers [7-11], recent studies indicate
that this DNA helicase is more involved in the DNA-
damage repair pathway. First, HLTF has been shown to
exhibit an E3 ubiquitin ligase activity for the polyubiqui-
tination of proliferating cell nuclear antigen (PCNA),
which is required for the initiation of an error-free repli-
cation through DNA damage lesions [12,13]. Second,
HLTF has also been found to display a double-stranded
DNA translocase activity, which promotes the resolution
of stalled replication forks at DNA damage lesions
[14,15]. Third, a recent study indicates that HLTF also
possesses a chromatin remodeling activity, which leads
to the displacement of DNA-bound proteins on stalled
replication forks and facilitates DNA-damage repair
[16]. These findings demonstrate that HLTF may be a
functional homologue of yeast rad5 and that it plays an
important role in an error-free post-replicative repair
pathway. The requirement of HLTF for repair of
damaged DNA may also implicate a tumor suppression
role in human colon cancers, where HLTF has been
identified as a common target for methylation and epi-
genetic gene silencing.
Epigenetic inactivation of HLTF gene expression by
promoter hypermethylation has been reported in more
than 40% of human colon cancers [17-20]. The fre-
quency of HLTF promoter methylation was found to
increase drastically between early stage of adenomas and
advanced adenomas, suggesting that this epigenetic
alteration could be a later event in colon carcinogenesis
[17,19]. In addition, HLTF methylation was demon-
strated to be significantly correlated with poor prognosis
in human colon cancer patients [21,22]. Besides colon
tumors, HLTF methylation was also commonly detected
in human gastric tumors or cancers, but not in other
human cancers, such as lung and breast cancers
[17,23-25], suggesting that this epigenetic alteration is
unique to the tumors of the gastrointestinal tract. How-
ever, although HLTF methylation has been demon-
strated as a common event in human colon cancer and
it has been suggested as a prognostic biomarker [22,26],
it is largely unclear whether this epigenetic event is
important for the development of this cancer. In the
present study, we generated an Hltf deficient mouse
allele, and applied this mouse model to characterize the
role of loss of HLTF function in the development of
intestinal cancer. Our data demonstrates that loss of
Hltf has a promoting effect on the transition of intest-
inal adenomas to invasive cancers, which highly suggests
that aberrant HLTF methylation, as found in most
human colon cancers, may have an important pathoge-
netic role in the development of this cancer.
Results
Generation of the Hltf null mouse allele
To study the loss of function of Hltf in vivo, we mutated
Hltf in mice by homologous recombination. A gene-tar-
geting vector was generated to replace the exons 1-5
coding for residues 2-208 of Hltf with a nuclear loca-
lized LacZ (nls-LacZ)c D N At h a tw a sf u s e di n - f r a m e
with the endogenous Hltf starting codon (Figure 1A).
Correct homologous recombination in the targeted ES
cells was confirmed by Southern blot analysis using
both 5’ and 3’ probes located upstream and downstream
of the targeted Hltf sequence (Figure 1B and 1C). Two
independent ES clones were used to produce germline-
transmitting chimeras that were further bred with a ubi-
quitous Cre transgenic line (EIIa-Cre) to delete the loxP
flanked pGK-neo selection marker from the targeted
locus (Figure 1A). The resultant Hltf
+/- mouse, which
was maintained on either a C57BL/6 or C57BL/6/129S1
background, was used to produce Hltf homozygous
mutant mice for phenotypic characterization.
To determine whether Hltf expression is completely
inactivated in Hltf
-/- mice, we performed Northern blot
analysis of total RNA prepared from control and mutant
E10.5 embryos. Whereas Hltf transcripts were identified
in control (wild-type and Hltf
+/-)e m b r y o su s i n gt h e5 ’
and 3’ Hltf cDNA probes, transcripts were not detected
in Hltf
-/- samples (Figure 1D). To further demonstrate
the absence of Hltf expression in Hltf
-/- mice, we also
applied a more sensitive real time RT-PCR assay to
examine the expression of Hltf in derived Hltf
-/- mouse
embryonic stem (ES) cells or mouse embryonic fibro-
blast (MEF) cells as well as in Hltf
-/- E10.5 embryos.
With the primer set located on the 3’ of Hltf cDNA, a
strong amplification of Hltf was detected in the control
group, but no signal was found in Hltf
-/- samples (Fig-
ure 1E). These data clearly indicate that the targeted
mutation that we introduced into the Hltf mouse geno-
mic locus gave rise to a null allele.
Normal development and lack of intestinal tumors in Hltf
null mice
With the established Hltf null allele, we then asked
whether loss of Hltf function could affect mouse devel-
opment and induce the formation of intestinal tumors.
As a first approach to address this, we determined the
expression pattern of Hltf during development. We took
advantage of the inserted nls-LacZ reporter gene in Hltf
knockout mice, whose expression is controlled by the
endogenous Hltf regulatory elements. Both Hltf
+/- and
Hltf
-/- mice showed the same LacZ expression pattern.
By determining LacZ activity in these mice, we found
that Hltf was specifically expressed in the heart at an
early developmental stage (E8.5 to E9.5) (Figure 2A).
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with LacZ signals detected in somites, branchial arches,
limb bud and brain (Figure 2B). At later embryonic
developmental stages, such as E16.5, Hltf showed wide
a n ds t r o n ge x p r e s s i o ni nm a n y tissues, including heart,
lung, liver, kidney, spleen and pancreas (Figure 2C).
This wide-spread expression of Hltf was also observed
in adult mice (data not shown). In both adult intestine
and colon, Hltf expression was mainly detected in the
crypts and in the intestinal epithelial cells (Figure 2D).
This broad expression pattern of Hltf during mouse
development might suggest that Hltf is important for
development. However, Hltf
-/- mice were found to have
normal embryonic and postnatal development. The Hltf
null mice were fertile, and exhibited similar a body
weight and life span as their wild-type (wt) littermates.
Figure 1 Targeted disruption of Hltf in mice by homologous recombination. (A) Schematic representation of the first 7 exons of the mouse
Hltf locus, the gene-targeting vector, and the mutant alleles. The location of the hybridization probes (5’ probe and 3’ probe) for Southern blot
analyses are shown. (B) Southern blot analysis of targeted ES cell clones using 5’ probe. The genomic DNA was digested with BamH1 and
hybridized with the 3’ probe, giving a wild-type allele of 8.7 kb and a mutant allele of 5.6 kb. (C) Southern blot analysis with the 3’probe,
showing the targeted allele with a size of 8.8 kb and the wild-type allele of 12.1 kb fragment upon EcoRI digestion. (D) Northern blot analysis of
Hltf transcripts in the E10.5 embryos of the indicated genotypes using cDNA probes that cover 5’ and 3’ coding sequence of Hltf, respectively.
The 28S and 18S ribosomal RNAs are shown as loading controls. (E) Real-time RT-PCR for detecting the 3’ coding sequence of Hltf in derived Hltf
-/- ES cells. The presented relative expression was normalized to the expression of Gapdh.N oHltf transcripts were detected in Hltf
-/- samples by
both Northern blot and real-time RT-PCR assays.
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-/- mice did not display obvious
abnormalities of intestinal proliferation or differentiation
as determined by the BrdU incorporation assay as well
as by the analyses with different intestinal cell lineage
markers (Additional file 1 and Additional file 2). To
determine whether loss of Hltf function could induce
the formation of intestinal tumors, we monitored a
cohort of 60 mice fed with a normal diet for a two-year
period (30 Hltf
-/- mice on C57BL/6 background and 30
wt mice matched for age and genetic background). Simi-
lar to the wt control group, 10% of Hltf
-/- mice (3 out
of 30) developed liver tumors or lymphomas between 16
Figure 2 Expression of Hltf during mouse development. The analysis was done by determining the activity of LacZ in Hltf knockout mice in
which the lacZ reporter was fused in-frame with the endogenous Hltf start codon. (A) Whole mount X-gal staining of E8.5 and E9.5 Hltf
+/-
embryos, demonstrating the specific expression of Hltf in heart (arrows indicate). (B) Whole mount X-gal staining of E10.5 Hltf
+/- embryos shows
broad expression of Hltf. (C) X-gal staining of tissues collected from E16.5 Hltf
+/- embryos. Hltf was found to be widely expressed in many tissues
at this developmental stage. (D) X-gal staining of intestine and colon from two-month old Hltf
+/- mice. Hltf was identified to be predominately
expressed in the crypts as well as in the intestinal epithelial cells in both intestine and colon.
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-/- mice formed
intestinal tumors or gastric tumors.
Taken together, our results demonstrate that Hltf is
dispensable for normal development. Our work also
indicates that loss of Hltf function by itself is insufficient
to drive the oncogenic process in the gastrointestinal
tract, which implicates that the epigenetic inactivation
of HLTF, as commonly found in human colon cancers,
could be involved in the late stage of intestinal tumor
development.
Development of intestinal cancers in Hltf
-/-/Apc
min/+
mutant mice
To determine whether the loss of HLTF function could
have a role in the progression of intestinal tumors, we
introduced the Hltf null mutation into Apc
min/+ mice.
The Apc
min/+ mice harbor a premature stop codon in
one allele of the Apc tumor suppressor gene, and
develop multiple intestinal adenomas that mimic human
familial adenomatosis polyposis [27]. The adenomas in
Apc
min/+ mice rarely progress to invasive intestinal or
colon cancers [28], making this mouse model an excel-
lent genetic tool for studying the later events involved
in intestinal carcinogenesis.
To avoid strain-specific modification of the Apc
min/+
intestinal tumor phenotype [29,30], we generated Hltf
-/-/Apc
min/+ mice on the C57BL/6 background. Hltf
-/-/Apc
min/+ mice became moribund at a similar age
as Apc
min/+ mice. Post-mortem examination revealed
that Hltf
-/-/Apc
min/+ and Apc
min/+ mice developed
similar numbers of tumors in the small intestine
(average of 65 macroscopic tumors/per mouse in both
groups). However, upon histological characterization,
most Hltf
-/-/Apc
min/+ mice (24 out of 30) were found
to form invasive intestinal adenocarcinomas charac-
terized by deeper invasion of tumor cells into the
muscularis propria (Figure 3B and Additional file 3).
The invaded neoplastic glandular cells exhibited high
b-catenin activity as reflected by the nuclear accumu-
lation of b-catenin detected by immmuno-staining
with anti-b-catenin antibody (Figure 3B). In contrast,
most Apc
min/+ mice developed only well-defined tubu-
lar adenomas or adenomas within the lamina propria
(Figure 3A).
Hltf
-/-/Apc
min/+ mice were also found to develop a
similar number of neoplastic lesions in the colon as
Apc
min/+ mice (average of 1.5 macroscopic tumors/per
mouse). Histologically, although both Hltf
-/-/Apc
min/+
and Apc
min/+ colon tumors showed tumor growth with
a pedunculated morphology protruding into the colonic
lumen, the majority of Hltf
-/-/Apc
min/+ colon tumors
displayed a more dramatic glandular atypia that resulted
in the formation of numerous mucin-filled cysts (Figure
4A, B), a characteristic pathological feature for human
colon cancers [31]. In addition, most Hltf
-/-/Apc
min/+
colon tumors were also found to have a strong desmo-
plastic stromal reaction, suggesting invasion of the
lamina propia (Figure 4B). Furthermore, Hltf
-/-/Apc
min/+
colon tumors were also found to have stronger and
more ubiquitous nuclear-stained b-catenin signals than
the tumor cells in Apc
min/+ mice (Figure 4C). These
data indicate that colon tumors from Hltf
-/-/Apc
min/+
mice had progressed to much higher grades than those
from Apc
min/+ mice. To further demonstrate the malig-
nancy of colon tumors developed in Hltf
-/-/Apc
min/+
mice, we derived cells from these tumors and then sub-
cutaneously injected them into Rag1
-/-/IL2
-/- immunode-
ficient mice. Within 30 days after injection, these cells
formed subcutaneous tumors that maintained the mor-
phological and immunohistochemical features of the
parental colon tumors (Figure 4D). This capability of
propagating tumor cells into another host, which was
not observed with cells derived Apc
min/+ colon tumors,
further supports that many colon tumors developed in
Hltf
-/-/Apc
min/+ mice could be malignant cancers.
Collectively, our results demonstrate that loss of Hltf
function is able to promote intestinal or colonic carcino-
genesis in mice with a mutant Apc background. This
finding, together with human epigenetic evidence that
HLTF is frequently silenced in the advanced human
colon adenomas or cancers but uncommonly in early
adenomas [17,19], indicates that epigenetic inactivation
of HLTF could be an important event involved in the
transition of benign adenomas to malignant colon
cancer.
Chromosomal instability in Hltf
-/-/Apc
min/+ colon tumor
cells
Chromosomal instability (CIN) is a genetic hallmark of
most human colon cancers, and it has been demon-
strated to be important for the progression of colon
tumors by increasing the rate of genetic aberration
[2,32,33]. Since HLTF has been shown to be required
for the maintenance of genomic stability [12-16], it is
likely that intestinal or colonic tumors developed in Hltf
-/-/Apc
min/+ mice would have increased genomic instabil-
ity. To examine this, we analyzed metaphase spreads
generated from tumor cells (passage 2) derived from
colon tumors developed in Apc
min/+ and Hltf
-/-/Apc
min/
+ mice. These tumors all showed pronounced cribiform
tumor growth without invasive neoplastic glands and
were histologically characterized as late stage colonic
adenomas.
Consistent with previous findings [34,35], colon tumor
cells from Apc
min/+ mice showed a near-diploid karyo-
type and did not harbor obvious chromosomal abnorm-
alities (Figure 5A). In contrast, three colon tumor cell
lines derived from Hltf
-/-/Apc
min/+ mice displayed an
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totype (SKY) analysis on these tumor cells further
revealed a high incidence of genetic alterations in the
forms of nonreciprocal translocations, chromosomal
fusions (which include both dicentric chromosomes and
centromeric fusions), and chromosomal fragments and
breaks (Figure 5D-G and Table 1). In addition, many
chromosomal fusions in Hltf
-/-/Apc
min/+ colon tumor
cells were found to lack telomere signals (Figure 5I),
indicating the presence of telomere dysfunction in these
tumor cells. Collectively, these results demonstrate that
Hltf
-/-/Apc
min/+ colon tumors had gross chromosomal
abnormalities, similar to the CIN phenotype as
described in most human colorectal cancers.
Figure 3 Loss of Hltf function enhances the formation of intestinal adenocarcinomas on Apc mutant background. (A) Haematoxylin-
eosin staining of representative intestinal tumors developed in Apc
min/+ mice, showing the formation of a well-defined tubular adenoma within
the lamina propria in these mice. (B) Two representative intestinal adenocarcimas from Hltf
-/-/Apc
min/+ mice. Arrowhead indicates tumor invasion
through the submucosa and into the muscularis propria. Immuno-staining with anti-b-catenin antibody also demonstrated that the invasive
neoplatic glands contained high b-catenin activity as reflected by the nuclear accumulation of b-catenin signals (indicated by arrowheads)
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HCT116 human colon cancer cells with HLTF knockdown
To determine whether loss of HLTF function would also
lead to a similar tumor-promoting effect in human
colon cancer as we demonstrated in the Hltf
-/-/Apc
min/+
mouse model, we applied a lentiviral based shRNA
knockdown approach to down-regulate HLTF expres-
sion in HCT116 human colon cancer cells. HCT116
cells are one of a few colon cancer cell lines that lack
HLTF promoter methylation [17], and express high
levels of HLTF (Figure 6A). In addition, these cells are
near-diploid with a stable karyotype [36], which would
also allow us to determine whether loss of HLTF func-
tion in human colon cancer cells could induce chromo-
somal abnormalities in a manner similar to the Hltf-
deficient mouse colon tumor cells.
As shown in Figure 6B, HLTF expression was signifi-
cantly reduced to almost undetectable protein level in
the transduced HCT116 cells that were stably integrated
with HLTF shRNAs (HCT116
HLTFshRNA1 and
Figure 4 Hltf
-/-/Apc
min/+ mice develop malignant colon tumors that are transplantable into another host. (A) Haematoxylin-eosin staining
of representative colon tumors collected from Apc
min/+ mice, showing pronounced tumor growth a pedunculated morphology protruding into
the colonic lumen (indicated by arrow). (B) Representative colon tumors collected from Hltf
-/-/Apc
min/+ mice, demonstrating the formation of
numerous mucin-filled cysts within tumors (white arrowheads) and strong desmoplastic stromal reaction. (C) Immuno-staining with anti-b-
catenin antibody. Hltf
-/-/Apc
min/+ colon tumors had stronger and more ubiquitous nuclear-stained b-catenin signals than the tumor cells in
Apc
min/+ mice. Arrowheads indicate the tumor cells with nuclear-stained b-catenin. (D) The formation of subcutaneous tumors from derived Hltf
-/-/Apc
min/+ colon tumor cells in Rag1
-/-/IL2
-/- immunodeficient mice. The subcutaneous tumors displayed neoplastic glandular structures, which
contained strong nuclear-stained b-catenin signals and were also positive for Villin, a marker for intestinal epithelial cells. Arrows indicate the
tumor, whereas arrowheads mark the subcutaneous muscle layer.
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HLTFshRNA2)a sc o m p a r e dt ot h es c r a m b l e
shRNA control (HCT116
Scramble). To determine whether
this down-regulation of HLTF expression was able to
modulate HCT116 tumor growth, HCT116 cells with or
without HLTF knockdown were injected subcutaneously
into Rag1
-/-/IL2
-/- immunodeficient mice. All the mice
with injected tumor cells (10
5 cells/per mouse) devel-
oped subcutaneous tumors within 20 days. However, the
tumors formed by HCT116
HLTFshRNA1 or
HCT116
HLTFshRNA2 cells showed significantly increased
Figure 5 Gross chromosomal instabilities in Hltf
-/-/Apc
min/+ colon tumors as revealed by cytogenetic analysis.( A )R e p r e s e n t a t i v e
metaphase spread of Apc
min/+ colon tumor cells as revealed by Giemsa staining, showing a near-diploid karyotype without obvious
chromosomal abnormalities in these tumor cells. (B) Giemsa staining of metaphase spreads prepared from Hltf
-/-/Apc
min/+ colon tumor cells,
which displayed aneuploid and gross chromosomal instability. (C) Summary of the average number of chromosomes in derived colon tumor
cells from Apc
min/+ and Hltf
-/-/Apc
min/+ mice. (D) Representative spectral karyotyping (SKY) image from Hltf
-/-/Apc
min/+ colon tumor cells. (E-I)
Some commonly detected chromosomal abnormalities in Hltf
-/-/Apc
min/+ colon tumor cells. E: Robertsonian fusions; F: Dicentric chromosomes;
G: Unbalanced chromosomal translocations; H: Chromosomal breaks. I: Telomere dysfunction as revealed by Q-FISH. A white arrow indicates
chromosomal fusion without telomeres at the fusion site, and a white arrowhead points to lack of telomere signals at the fusion site of a
dicentric chromosome ring.
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-/-Apc
min/+ mice
Genotype
of tumors
Metaphase Analyzed Aneuploidy (%)
a Translocations (%) End-to-End Fusions (%)
b Fragments (%) Breaks (%)
Apc
min/+ 20 3 (15%) 0 0 0 0
Hltf
-/-/Apc
min/+ 20 17 (85%) 7 (35%) 9 (45%) 16 (80%) 3 (15%)
Hltf
-/-/Apc
min/+ 33 31 (93%) 10 (32%) 21 (63%) 15 (50%) 4 (20%)
Hltf
-/-/Apc
min/+ 20 20 (100%) 3 (15%) 4 (20%) 1 (5%) 4 (20%)
a Expressed as percentage of cells with other than 40 chromosomes (each Robertsonian fusion counted as two chromosomes).
b Expressed as total number of end-to-end associated chromosomes per metaphase, including dicentric chromosomes, telomere associations and Robertsonian
fusions
Figure 6 Down-regulation of HLTF in human HCT116 colon cancer cells promotes tumor growth. (A) Western blot analysis with anti-HLTF
antibody on the cell lysates prepared from HLTF methylated human colon cancer cells (RKO and SW480) and HLTF unmethylated human colon
cancer cells (HCT116). (B) Western blot analysis on the cell lysates prepared from HCT116 cells that were stably integrated with scramble control
shRNA and HLTF shRNAs. HLTF expression was efficiently inhibited by two independent HLTF shRNAs. (C) Representative image of subcutaneous
tumors formed from HCT116
Scramble, HCT116
HLTFshRNA1 and HCT116
HLTFshRNA2 cells in Rag1
-/-/IL2
-/- immunodeficient mice. (D) Haematoxylin-eosin
staining demonstrates that both HLTF knockdown tumors displayed tumor cell invasion into the muscle layer (indicated by arrows) which was
not typically observed in the scramble control tumors. HLTF knockdown tumors also showed low expression of HLTF as detected by immuno-
staining with anti-HLTF antibody.
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trol (Figure 6C). Moreover, both HCT116
HLTFshRNA1
and HCT116
HLTFshRNA2 subcutaneous tumors also fre-
quently exhibited the invasion of tumor cells into the
subcutaneous muscle layer that was uncommonly
observed in the control tumors (Figure 6D). To confirm
that HLTF expression was indeed down-regulated in
these tumors, we performed immunohistochemistry
with an anti-HLTF antibody. Both HCT116
HLTFshRNA1
and HCT116
HLTFshRNA2 subcutaneous tumors showed
significantly lower expression of HLTF as compared to
the scramble control tumors (Figure 6D). Taken
together, our data indicate that down-regulation of
HLTF in human colon cancer cells may promote tumor
growth and malignancy, similar to what we found in the
Hltf
-/-/Apc
min/+ mouse model.
We then performed cytogenetic analysis to determine
whether down-regulation of HLTF expression in human
colon cancer cells induced chromosomal abnormalities.
Detailed SKY analysis of metaphase spreads from both
short term (10 days) cultured HCT116 parental cells
and HCT116
scramble cells revealed the presence of near-
diploid chromosomes with a few highly conserved chro-
mosomal translocations (Figure 7A), consistent with the
documented karyotype for HCT116 parental cells [37].
This near-diploid karyotype was also observed in the
second generation of HCT116 cells and HCT116
scramble
cells that were derived from the subcutaneous tumors
formed by these cells (Figure 7C), further indicating that
H C T 1 1 6c e l l sh a v eas t a b l ec h r o m o s o m ek a r y o t y p ea s
demonstrated previously [38,39]. In contrast, both short-
term cultured and the second generation of
HCT116
HLTFshRNA1 and HCT116
HLTFshRNA2 tumor cells
exhibited significantly increased chromosomal abnorm-
alities in the forms of chromosomal loss and chromoso-
m a lf u s i o n sa n db r e a k sa sc o m p a r e dt ot h ec o n t r o l
groups (p < 0.001) (Figure 7B-C). In addition, approxi-
mately 15% of metaphases from HCT116
HLTFshRNA1 and
HCT116
HLTFshRNA2 tumor cells showed high numbers
of trisomy (Figure 7D). These results clearly indicate
that down-regulation of HLTF in human colon cancer
cells is able to induce chromosomal abnormalities.
Discussion
There is now strong evidence that a series of genetic
alterations are required for the pathogenesis of human
colon cancer. Specific gene mutations, such as in the
APC gene, initiate the formation of colonic adenomas
and others (e.g. TP53 mutations as well as other altera-
tions, including KRAS activation) drive the malignant
transformation of the adenomas in a multistep progres-
sion model [2,3]. More recently, epigenetic alterations,
specifically aberrant DNA methylation, have been found
to occur commonly in colon cancers [4,5]. Although
there is controversy regarding the significance of these
alterations in the pathogenesis of colon cancer, more
and more data indicate that the aberrant methylation of
at least some of these genes, such as MLH1 (MutL
homolog 1), MGMT (O-6-methylguanine-DNA methy-
transferase) and HIC1 (hypermethylated in cancer 1)
can be pathogenetic in colorectal carcinogenesis [2,6].
Here, we have added another example to demonstrate
the importance of epigenetic alterations in this
carcinogenesis.
In this study, we focused on determining the role of
loss of HLTF function in the development of colon can-
cer. The HLTF promoter has been found to be hyper-
methylated in more than 40% of human colon cancers
[17-20], suggesting that HLTF is a common target for
methylation in this cancer. All colon cancer cells that
lacked HLTF expression had the methylation of CpG
islands within the HLTF promoter, while methylation
was not detected in the HLTF-expressing cells [17] (Fig-
ure 6A), further indicating that this epigenetic event
leads to a complete inactivation of HLTF expression in
colon cancer cells. To determine the role of loss of
HLTF function, in this study, we generated Hltf deficient
mice (Figure 1). Although these mice did not develop
intestinal or colonic tumors, the majority of them were
found to develop invasive intestinal and colonic cancers
upon Apc mutation-mediated tumor initiation (Figures
4 and 5). Our results strongly suggest that aberrant
methylation of HLTF, which leads to the loss of this
gene’s function as found in most human colon cancers,
could have a pathogenetic role rather than being a con-
sequence of colorectal carcinogenesis. This epigenetic
event could be important for driving the transition of
benign adenomas to the malignant adenocarcinomas,
which is consistent with human tumor data showing
that HLTF promoter methylation is mainly detected in
the advanced colonic adenomas and cancers, but not in
the early stage of adenomatous polyp [17,19]. The high
frequency of HLTF promoter hypermethylation observed
in these tumors indicates that the silencing of this gene
could confer a selective advantage for the progression of
these tumors to the malignant cancers.
Although the mechanism by which loss of HLTF func-
tion results in this malignant transformation still needs
to be defined, our data demonstrating gross chromoso-
mal abnormalities in Hltf deficient colon tumor cells
may suggest that genomic instability induced in these
tumors is a driving force for this carcinogenesis. Geno-
mic instability is a characteristic of human colon can-
cers, and has been implicated in the initiation and
progression of these cancers by increasing the rate of
genetic alterations [2]. Two types of genetic instability
have been found in human colon cancer: microsatellite
instability (MIN) and chromosomal instability (CIN).
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Page 10 of 16Figure 7 HLTF knockdown induces chromosomal abnormalities in HCT116 colon cancer cells. (A) Representative SKY image of
HCT116
scramble cells, showing a stable karyotype with 45 total chromosomes, der(10)t(10;6) (white arrow), der(16)t(8;16) (white arrowhead) and
der(18)t(17;18) (yellow arrow), a documented signature for HCT116 parental cells. (B) Representative SKY images of HLTF knockdown HCT116
cells. Several additional chromosomal abnormalities were identified, which include chromosomal fragment (yellow arrowhead), monosomy
chromosome 3 (white arrow), der(15) (15;11) (white arrowhead) and der(16) (16;22) (yellow arrow). (C) The number of structural chromosomal
abnormalities in HCT116 cells with and without HLTF knockdown. Two groups of cells were analyzed, one from a short term in vitro culture (10
days) and another from subcutaneous tumors that were generated by these cells. The horizontal bars indicate the mean numbers of
chromosomal abnormalities in each population of cells. Each data point represents the total number of structural chromosomal rearrangements
per metaphase spread after subtraction of the rearrangements (i.e. stable present translocations) found in HCT116 parental cells. (D)
Representative SKY images of HLTF knockdown HCT116 cells, demonstrating the presence of high number of trisomies in the tumor cells
(indicated by arrows)
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obvious chromosomal defects but have high incidence
of instability in microsatellite repeats linked to impaired
mismatch repair (MMR) [40]. The predominant
mechanism identified to inactivate MMR in these
tumors is epigenetic silencing through promoter methy-
lation [41], although somatic mutations in MMR genes
also occur [42]. CIN, which accounts for 85% of colorec-
tal cancers, exhibits aneuploid, allelic losses and other
chromosomal abnormalities, such as translocation,
fusion and breaks [32]. Colon cancers with CIN pheno-
type have been found to behave more aggressively in
terms of invasiveness and metastasis [32]. Although its
molecular basis remains largely elusive, CIN is thought
to arise from structural defects involving centromere or
centrosome, microtubule dysfunction, telomere defects,
chromosomal fragility and cell cycle checkpoint failure
[2,6]. In this work, we have provided solid evidence that
Hltf deficient mouse colon tumors display severe chro-
mosomal abnormalities, similar to CIN as described in
human colon cancers (Figure 5). We have also demon-
strated that down-regulation of HLTF increased chro-
mosomal abnormalities in human colon cancer cells
(Figure 7). Furthermore, similar to human colon cancers
with a CIN phenotype, we have also found that Hltf
deficient mouse colon tumors or HLTF knockdown
human colon cancer cells developed more malignant
features, such as invasiveness, as compared to the tumor
cells that contain functional HLTF (Figures 4, 5 and 6).
All these findings indicate that the genomic instability
induced in HLTF deficient colon tumors likely plays an
important role in the malignant transformation of these
tumors. Future studies using our established Hltf knock-
out mouse colon tumor model to identify the genetic
mutations involved in this pathogenesis have the poten-
tial to provide a deeper understanding of colon cancer
development.
The presence of a CIN phenotype in Hltf knockout or
knockdown tumor cells also implicates loss of HLTF
function as an additional mechanism to induce CIN
phenotypes in human colon cancer. The involvement of
HLTF in the post-replicative DNA damage-repair path-
way has been demonstrated by several recent studies
[12-16]. In these work, HLTF was shown to display a
similar function as yeast rad5 in the polyubiquitination
of PCNA, which is required fori n i t i a t i n ga ne r r o r - f r e e
post-replicative repair activity [12,13]. HLTF was also
found to have both DNA translocase and chromatin
remodeling activities to facilitate the repair of damaged
DNA on stalled replication forks [14-16]. Therefore,
HLTF could be an important factor in the post-replica-
tive repair pathway. Without HLTF, it is likely that the
progression of the replication fork would be blocked at
DNA damage lesions, resulting in an accumulation of
DNA intermediates that trigger recombination and
genomic instability [43]. Our cytogenetic data demon-
strating the gross chromosomal abnormalities present in
Hltf d e f i c i e n tm o u s et u m o ro ri nH L T Fk n o c k d o w n
HCT116 colon cancer cells strongly support this notion.
Our data also agree with many other studies indicating
that aberrant post-replicative repair activity is a major
source of the mutations and chromosome rearrange-
ments that could be important for tumorigenesis. Inter-
estingly, mice deficient in Hltf alone were found to
develop normally and did not display any pathological
disorders associated with genetic instability. This may
due to the robust replication checkpoints present in
normal mouse cells, which, upon DNA damage, could
boost a DNA damage response that arrests cells that
harbor unrepaired DNA damage [44]. These unrepaired
cells could undergo apoptosis and then be replenished
by cells differentiated from a pool of progenitor and
stem cells during development. However, when these
checkpoint pathways are not functional, the cells that
contain defective or unrepaired DNA lesions could still
progress through the cell cycle, resulting in broken
chromosomes, genome aberrations and an accumulation
of mutations [44,45]. A recent study indicates that APC
could play an important role in the DNA replication
checkpoints by stabilizing the association of DNA repli-
cation complexes at stalled DNA replication forks [46].
Consistent with this finding, tumor cells that have lost
APC function, such as human SW480 colon cancer
cells, have been found to lose the capacity to arrest cells
with damaged DNA [46]. Therefore, Hltf
-/-/Apc
min/+
colon tumor cells may have impaired replication check-
points, which could facilitate cell cycle progression to
enhance the genomic instability in these tumor cells.
HLTF has also been demonstrated to interact with
several different gene promoters and enhancers [7-11],
suggesting its potential role in the regulation of gene
expression. We recently performed micoarray-based
gene expression analyses and did not find significant
changes of gene expression between Hltf
+/+ and Hltf
-/-
mouse ES cells or in HCT116 cells with and without
HLTF knockdown. In both cases, a very few genes
showed 2-fold change with the statistical significance
(Additional file 4). None of these genes have been impli-
cated in tumorigenesis or in the maintenance of geno-
mic stability. Therefore, the loss of HLTF function is
unlikely to mis-regulate the expression of specific genes,
leading to the development of colon cancers.
Conclusions
We have provided direct genetic evidence that loss of
HLTF function promotes the malignant transformation
of intestinal or colonic adenomas to carcinomas. We
have also demonstrated that this pathogenetic outcome
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tenance of genomic stability. Given the high frequency
of epigenetic inactivation by hypermethylation of HLTF
in human colon cancers, our studies strongly suggest
that this epigenetic alteration could be directly involved
in the development of colon cancer rather than a conse-
quence of this carcinogenesis.
Methods
Construction of Hltf gene-targeting vector
The Hltf gene-targeting vector was generated based on a
PCR-based cloning strategy [47]. Briefly, the mouse Hltf
genomic fragments required for the 5’ and 3’ arms of
homology were PCR-amplified from the genomic DNA
of R1 ES cells (on 129S1 background) with a high-fide-
lity polymerase (TaKaRa). The primer sequences are
listed in Additional file 5. After validation by DNA
sequencing, the Hltf 5’arm DNA fragment was ligated
upstream of a nlsLacZpA-loxP-pGKneo-loxP cassette.
This vector was further inserted by a DNA fragment
containing Hltf 3’arm and pGK-DTA cassette to gener-
ate the final gene-targeting vector that contains Hltf
5’arm-nlsLacZpA-loxP-pGKneo-loxP-Hltf 3’arm-pGK-
DTA (Figure 1A).
Generation of Hltf deficient mice
The Hltf gene-targeting vector was linearized with SacII
and then electroporated into R1 ES cells. The trans-
fected ES cells were selected with G418 (250 μg/ml),
and G418-resistant ES clones were screened by South-
ern blot analysis for the correctly targeted allele using
BamHI( f o rt h e5 ’ external probe) and EcoRI( f o rt h e3 ’
external probe) digestions. Both the 5’ and 3’ external
probes were PCR amplified with primers listed in Addi-
tional file 5. Two independently targeted ES cell clones
were used to generate chimeric mice by ES cell⇔diploid
embryo aggregation. Transmitting chimeric males were
crossed with an EIIa-Cre line (Jackson laboratories, Bar
Harbor, Maine) to delete the loxPf l a n k e dneo cassette
from the targeted allele. The resultant mouse allele was
further bred with 129S1 females to produce hemizygous
transgenic offspring on 129S1/C57BL/6 background.
Hltf
+/- mice were also backcrossed to C57BL/6 for eight
generations. All mouse experiments were performed in
accordance with procedures approved by the University
of Manitoba Animal Care and Use Committee.
Genotyping
A PCR based genotyping method was applied to geno-
type Hltf knockout mice. Primers to amplify the targeted
allele were the sense primer (P1) (5’-GGAGCTTTAT-
CAGGCTGTCTGGGA-3’) and antisense primer (P2)
specific for the LacZpA cassette (5’-AGGAAGATCG-
CACTCCAGCCAGCT-3’). To detect the wild-type
HLTF allele, wt P1 primer (5’-GTCCATGTCCTAGC-
CATGAGTA-3’) and an antisense primer (P3) locating
in exon 1 (5’-GCTTGGTAAGGACTACAAAGCA-3’)
were used for PCR.
Mouse intestinal and colonic tumor analysis on Hltf/Apc
mutant mice
The Apc
Min/+ mice were purchased from The Jackson
Laboratory and maintained on a C57/B6 genetic back-
ground. These mice were bred with Hltf
+/- (C57/B6
background) to generate a cohort of Hltf
-/-/Apc
min/+,
Apc
min/+ and Hltf
+/-/Apc
min/+ mice for intestinal tumor
analysis. Mice were sacrificed by cervical dislocation,
and the entire small intestine and colon were flushed
with cold PBS and dissected longitudinally. The number,
location and size of tumors in the intestine or colon
were examined and recorded. Small intestinal and colo-
nic tumors were further histologically analyzed by hem-
toxylin/eosin staining and immunohistochemistry.
Establishment of colon tumor cells from Hltf/Apc mutant
mice and growth in Rag1
-/-/IL2
-/- immunocompromised
mice
Tumor cells from Hltf
-/-/Apc
min/+ and Apc
min/+ colon
tumors were generated as described [35]. The cells were
grown in 6 cm culture dishes plated with mitomycin-
treated mouse embryonic fibroblast (MEF) cells using
the culture conditions as described [35]. The early pas-
sage (p2) cells were collected either for tumorigenicity
analysis by injecting 10
5 cells subcutaneously to Rag1
-/-/
IL2
-/- mice (purchased from Jackson Laboratory), or for
cytogenetic characterization.
Immunohistochemistry (IHC)
IHC was performed as described previously [48]. Briefly,
dissected intestinal and colonic tumors were fixed in
10% formalin in PBS overnight. The fixed tissues were
embedded in paraffin, and 5 μm paraffin-embedded tis-
sue sections were pretreated with Retrieval solution
(Dako) and blocked with either mouse IgG blocking
reagent (Vector Laboratory) or serum free blocking
reagent (Dako), and then incubated with primary antibo-
dies overnight at 4°. Primary antibodies used were
mouse anti-BrdU (Roche, dilution 1:100), mouse anti-
Ki67 (BD Pharmingen, dilution 1:100), mouse anti-b-
catenin (BD Pharmingen, dilution 1:200), rabbit anti-
HLTF (Sigma, dilution 1:100) rabbit anti-lysozyme
(Dako, dilution 1:200), and rabbit anti-chromogranin A
(ImmunoStar, dilution 1:4000). After washing with TBS
containing 0.1% Tween20 buffer, sections were incu-
bated with biotinylated anti-rabbit or anti-mouse anti-
body for 60 min at room temperature. The sections
were washed 3 times with TBS-0.1% Tween20 buffer
and incubated with avidin-biotin-peroxidase complex
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protocol. Color was developed using metal 3,3’-diamino-
benzidine tetrachloride.
Lentiviral based shRNA knockdown of HLTF expression in
HCT116 cells
Lentiviral vectors expressing shRNA against human
HLTF (NM 003071, V2LHS 254799, _153142, _153143,
_153144, _153146) or scrambled control were obtained
from the GIPZ lentiviral shRNAmir library (Open Biosys-
tems, Thermo Scientifc) acquired at the University of
Manitoba. The pGIPZ lentiviral vector expresses a short
hairpin RNA modeled by human microRNA-30 (miR30)
primary transcript for increased Drosha and Dicer pro-
cessing. TurboGFP reporter gene and puromycin drug
resistance marker are expressed as part of a bicistronic
transcript. Preparation and infection of lentiviral particles
into HCT116 cells (from ATCC) were performed based
on an established procedure as described previously [49].
After infection, HCT116 cells were treated with 0.75 μg/
ml puromycin for four days. The puromycin-resistant
clones were pooled to determine HLTF expression by
Western blot analysis with anti-HLTF antibody (Sigma).
10
5 cells from these established stable cell lines were sub-
cutaneously injected to Rag1
-/-/IL2
-/- mice to determine
the effect of HLTF knockdown on tumor growth. These
cells, as well as cells derived from subcutaneous tumors,
were also utilized for cytogenetic analysis.
Cytogenetic analysis
Metaphase spreads for SKY analysis were performed
using the SKT kit (ASI) according to the manufacturer’s
instructions and previously published methods [50]. In
each cell line, at least 20 metaphase spreads were stu-
died. Q-FISH analysis was performed as previously
described [51].
Northern blot analysis
Total RNA from freshly dissected mouse E10.5 embryos
was extracted using TRIzol (Life Technologies, Inc.). 20
μg of total RNA was separated on a 1% agarose-formal-
dehyde gel and transferred to Hybond nylon membrane
(Amersham). Hybridization was carried out in Per-
fectHyb (Sigma) with 1.5 × 10
6 cpm/ml of 5’ and 3’ Hltf
cDNA probes. Both 5’ and 3’ cDNA probes were PCR-
amplified with the primers listed in Additional file 5.
X-gal staining
Dissected mouse embryos or tissues were fixed for 30
min (for E8.5 to E9.5) or 60 min (for E10.5 embryos and
tissues) with 4% paraformaldehyde (PFA), 0.2% glutaral-
dehyde and 0.02% NP-40 in PBS. Subsequently, fixed
samples were washed three times with PBS containing
0.02% NP-40, and stained at 37°C overnight with a
staining solution containing 4 mM K4Fe(CN)6,4m M
K3Fe(CN)6, 2 mM MgCl2, and 0.2% X-gal in PBS.
Western blot analysis
For Western blots, cells were lysed in RIPA buffer. 30
μg lysate was separated by 8% SDS-PAGE and trans-
ferred to nitrocellulose membrane, which was blocked
with 5% non-fat milk and incubated with rabbit anti-
HLTF antibody (Sigma, dilution 1:500) at 4° overnight.
Protein was detected using an enhanced chemilumines-
cence system (Amersham Life Science).
Statistical analysis
Ap a i r e dt-test (two tailed) was used to analyze the sta-
tistical significance of chromosomal abnormalities in
tumor cells. P < 0.05 was considered indicative of statis-
tical significance.
Additional material
Additional file 1: Loss of Hltf function does not affect the cellular
proliferation in small intestine and colon. The small intestines and
colons collected from 2-month old Hltf
+/+ and Hltf
-/- mice were stained
with Haematoxylin-eosin and anti-Brdu antibody. Both Hltf
+/+ and Hltf
-/-
intestine and colon displayed normal morphology and a similar number
of BrdU positive cells within the crypt (2 h after BrdU injection) and in
crypt-villus axis (24 h after BrdU injection).
Additional file 2: Loss of Hltf function does not affect the
differentiation of epithelial cells in small intestine and colon. The
small intestines and colons from 2-month old Hltf
+/+ and Hltf
-/- mice
were analyzed using several intestinal cell-lineage markers. The Goblet
cells were determined by staining with Alcian blue and periodic acid-
Schiff (PAS). The enteroendocrine cells were analyzed by immuno-
staining with anti-chromogranin A, and the Paneth cells in small intestine
were detected by anti-lysozyme antibody. Both Hltf
+/+ and Hltf
-/-
intestines or colons showed very similar staining patterns for these
markers.
Additional file 3: Hltf
-/-/Apc
min/+ mice frequently developed invasive
intestinal adenocarcinomas. Several additional Haematoxylin-eosin
stained images demonstrate the formation of invasive intestinal
adenocarcinomas (indicated by arrows) in Hltf
-/-/Apc
min/+ mice.
Additional file 4: List of genes that showed expression changes
between Hltf
+/+ and Hltf
-/- mouse ES cells and in HCT116 cells with
and without HLTF knockdown. The microarray expression assays were
carried out by the Center for Applied Genomics at the Toronto Hospital
for Sick Children. Three independent cell lines from each group were
analyzed. The changes with the statistical significance (p < 0.05) are
highlighted by yellow. Red indicates the change of gene expression
cannot be validated by real-time PCR.
Additional file 5: List of PCR primers that were applied in this
study.
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